Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Agilent's ClearSeq AML, Emory's Pan-Ethnic Carrier Screen Test


Agilent Technologies has launched ClearSeq AML, a next-generation sequencing-based panel that targets 48 exons in 20 of the most commonly mutated genes in acute myeloid leukemia. Agilent researchers designed the panel in collaboration with Robert Ohgami and Daniel Arber at Stanford University. The panel provides 99.9 percent design coverage of targeted exons, according to the company and is based on its SureSelect and HaloPlex technology.

Emory Genetics Laboratory has launched its Pan-Ethnic Carrier Screen test, which is based on next-generation sequencing. The test screens for 725 mutations across 145 genes related to more than 140 genetic disorders, including all mutations recommended for screening by the American College of Medical Genetics and Genomics and the American Congress of Obstetricians and Gynecologists.